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nonmalignant disorders (NMD) are complicated by early and
late treatment-related toxicities. We used a novel reduced
intensity conditioning (RIC) regimen with early administra-
tion of alemtuzumab to achieve donor engraftment with
lower toxicities in NMD. Delayed immune reconstitution (IR)
and severe/fatal late infections have been previously
described with RIC using alemtuzumab peri-SCT. Early
administration in our protocol is designed to selectively
deplete host immunity with minimal effects on post-trans-
plant IR.We report the kinetics of IR and infection patterns in
the ﬁrst year post-SCT with this approach.
Methods: HSCT was performed for marrow failure, genetic
diseases or immune disorders with alemtuzumab (day -22
to -19; 33 mg if < 10 kg; 48 mg if > 10 kg), ﬂudarabine (day
-8 to -4; 150 mg/m2), and melphalan (day -3; 140 mg/m2)
followed by infusion of matched related (MRD) or matched
unrelated (MUD) marrow/PBSC. GVHD prophylaxis included
a calcineurin inhibitor (6-9 m), short course methotrexate
(days 1, 3 and 6) and short course prednisone (28 d). Stable
engraftment (> 20% donor) occurred in 89% of patients.
Lymphocyte numbers, proliferation, and immunoglobulin
levels were measured at 3, 6 and 12 m. We evaluated 35
MRD and 31 MUD recipients with immune studies collected
at a minimum of two time periods after SCT and tracked
cumulative incidence of bacterial, viral and fungal
infections.
Results: Lymphocyte, NK, CD4 and CD8 T cell numbers and
immunoglobulin levels normalized by 6 months post SCT in
both groups. MUD SCT resulted in slower IR than MRD.
Notably, MUD recipients had lower B cells after 6 months
though immunoglobulin levels were normal. The kinetics of
recovery of immune function correlated with incidence of
infections, which were highest until day 100 and declined
after day 180.
Conclusions: SCT following RIC with early administration of
alemtuzumab resulted in successful donor marrow
engraftment and rapid IR within 6 months in contrast to
previous experience. Only B cell recovery was noted to be
slower in MUD compared to MRD transplants. This RIC
regimen supports early immune recovery with reduced
and more localized infectious complications after the ﬁrst
6 months. These results provide a context for reﬁning
infection surveillance, antibiotic prophylaxis, revaccination
and return to normal lifestyle devoid of infectious
complications.176
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Early lymphocyte recovery has shown to be associated
with superior survival in patients with hematological
malignancies following umanipulated haploidentical blood
and marrow transplantion (HBMT), but its effect on clinical
outcomes in patients with myelodysplastic syndrome (MDS)
and acute myeloid leukemia (AML) evolving from MDS is
